IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 77.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 374 shares of the medical research company’s stock after selling 1,314 shares during the period. Raleigh Capital Management Inc.’s holdings in IQVIA were worth $73,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Sei Investments Co. increased its holdings in shares of IQVIA by 42.1% during the 2nd quarter. Sei Investments Co. now owns 82,250 shares of the medical research company’s stock worth $17,390,000 after buying an additional 24,363 shares during the last quarter. ProShare Advisors LLC grew its position in IQVIA by 6.2% during the second quarter. ProShare Advisors LLC now owns 31,901 shares of the medical research company’s stock valued at $6,745,000 after acquiring an additional 1,858 shares during the period. Bank of Montreal Can increased its stake in IQVIA by 9.2% during the second quarter. Bank of Montreal Can now owns 245,711 shares of the medical research company’s stock worth $51,968,000 after acquiring an additional 20,799 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of IQVIA by 567.0% in the 2nd quarter. Marshall Wace LLP now owns 77,610 shares of the medical research company’s stock worth $16,410,000 after purchasing an additional 65,974 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of IQVIA by 60.0% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,860 shares of the medical research company’s stock valued at $7,371,000 after purchasing an additional 13,071 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI decreased their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Finally, TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Price Performance

Shares of IQV stock opened at $206.06 on Friday. The firm has a market cap of $37.40 billion, a P/E ratio of 27.04, a P/E/G ratio of 2.14 and a beta of 1.48. The firm has a fifty day moving average of $199.41 and a two-hundred day moving average of $221.19. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.